Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Acea Biosciences Inc.
DescriptionEpidermal growth factor receptor (EGFR) mutation selective tyrosine kinase inhibitor
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat local advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation or T790M drug-resistant mutation
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today